Myriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1
October 20 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will
hold its fiscal first-quarter 2017 sales and earnings conference
call with investors and analysts at 4:30 p.m. ET on Tuesday,
November 1, 2016. During the call, Mark C. Capone, president
and CEO and Bryan Riggsbee, CFO, will provide an overview of
Myriad’s financial performance for the fiscal first-quarter and
provide a business update.
To listen to the call, interested parties in the United States
may dial 800-735-5968 or +1 312-281-1210 for international
callers. All callers will be asked to reference reservation
number 21819980. The conference call also will be available through
a live webcast and a slide presentation pertaining to the earnings
call will also be available under the investor section of our
website at www.myriad.com. A replay of the call will be
available two hours after the end of the call for seven days and
may be accessed by dialing 800-633-8284 within the United States or
+1 402-977-9140 for international callers and entering reservation
number 21819980.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra, GeneSight and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024